Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discusses the difficulty reconciling recent important trials on radiotherapy for breast cancer: The Z11 trial suggested that breast tangents are sufficient, while MA.20 and EORTC studies suggested that full nodal irradiation is beneficial.
Vratislav Strnad, MD, PhD, of the University Hospital in Erlangen, discusses results from a European study comparing accelerated partial-breast irradiation using brachytherapy, to the standard treatment of whole-breast irradiation for women with low-risk breast cancer (Abstract LBA7).
Roy Decker, MD, PhD, of Yale University School of Medicine, discusses a National Cancer Database analysis that showed elderly patients with limited-stage small cell lung cancer can benefit from adding concurrent radiation to chemotherapy (Abstract 1010).
Catherine C. Park, MD, of the University of California, San Francisco, summarizes results from three clinical trials of radiation therapy for various cancers: metastatic melanoma, oropharyngeal squamous cell carcinoma, and breast cancer (Abstracts 215, 3, and LBA7).
Joel E. Tepper, MD, of the University of North Carolina School of Medicine, discusses the ways in which SBRT has changed radiotherapy, as demonstrated in key studies presented at this year's meeting on stereotactic body radiotherapy for liver metastases and hepatocellular carcinoma, and borderline resectable and unresectable pancreatic tumors (Abstracts 253, 255, 351, 357).
Anthony Zietman, MD, of Massachusetts General Hospital, discusses his perspective on the study of bicalutamide during and after radiotherapy in patients following radical prostatectomy and a biochemical relapse (Abstract LBA5).
